Hikal Limited Q3 FY26 Earnings Call Transcript Released
Hikal Limited reported Q3 FY26 consolidated revenue of ₹494 crore and EBITDA of ₹83 crore, marking a return to operational profitability. An interim dividend of ₹0.2 per share was approved. The Pharmaceutical segment revenue was ₹337 crore with a 12.3% EBIT margin. The Crop Protection segment revenue was ₹157 crore with a 3% EBIT margin. The company expects meaningful revenue from the Personal Care segment starting FY27.
The announcement provides an update on quarterly financial performance and operational progress, including specific revenue and EBITDA figures. The positive turnaround from previous challenges and strategic initiatives like diversification into Personal Care and growth in Animal Health are material developments for investors.
The company reported a return to operational profitability in Q3 FY26, with sequential improvements in demand and capacity utilization. Positive commentary on the recovery of both Pharmaceutical and Crop Protection businesses, along with strategic diversification into Personal Care and growth in Animal Health, indicates a positive outlook.
Hikal Limited has released the transcript of its earnings conference call for the quarter and nine months ended December 31, 2025, which was held on February 11, 2026. The company reported consolidated revenue of ₹494 crore and EBITDA of ₹83 crore for Q3 FY26, indicating a return to operational profitability. For the nine months ended December 31, 2025, revenue stood at ₹1,193 crore with an EBITDA of ₹115 crore. The Board of Directors approved an interim dividend of ₹0.2 per share (10% of face value).
The Pharmaceutical segment reported revenue of ₹337 crore with an EBIT margin of 12.3% for Q3 FY26. The company is progressing with its remedial actions concerning the U.S. FDA audit, with significant sequential improvement in volumes and capacity utilization. Investments in a high-potency laboratory and R&D centre in Pune, and a new pilot plant in Panoli are operational, enhancing its value proposition as a CDMO partner.
The Crop Protection segment recorded revenues of ₹157 crore with an EBIT margin of 3% for the quarter. The company is accelerating its portfolio diversification into specialty chemicals, particularly the Personal Care segment, with meaningful revenue expected from FY27. Investments in cost optimization initiatives are also underway.
The Animal Health business continues to see steady momentum, with ongoing long-term contracts and several RFPs for new development projects. The company aims to build this business into a ₹500 crore plus entity in the next 4 to 5 years.
Financially, the finance cost for Q3 FY26 reduced by 17% year-on-year due to lower debt and interest rates. An exceptional item of ₹38 crore was provided on account of new labor code charges, resulting in a reported loss for the quarter. Excluding this, profit before tax grew by 21% to ₹29 crore. Capital expenditure for the nine months period stood at ₹100 crore, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacities. The company ended FY26 with approximately ₹150 crore in capex.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.